Asthma, a chronic inflammatory disease is typically characterized by bronchoconstriction and airway hyper-reactivity. A wealth of studies applying chemistry, molecular and cell biology to animal model systems and human asthma over the last decade have revealed that asthma is associated with increased synthesis of the gaseous molecule nitric oxide (NO). The high NO levels in the oxidative environment of the asthmatic airway lead to greater formation of reactive nitrogen species (RNS) and subsequent oxidation and nitration of proteins, which adversely affect protein functions that are biologically relevant to chronic inflammation. In contrast to the high levels of NO and nitrated products, there are lower levels of beneficial S-nitrosothiols (RSNO), which mediate bronchodilation, due to greater enzymatic catabolism of RSNO in the asthmatic airways. This review discusses the rapidly accruing data linking metabolic products of NO as critical determinants in the chronic inflammation and airway reactivity of asthma.
Introduction
Asthma is a chronic disease of airway inflammation, typically characterized by bronchial hyper-responsiveness, airflow limitation and mucus hyper-secretion, leading to the symptoms of cough, wheezing and shortness of breath [1] [2] [3] . Although many pathologic processes participate in asthma pathogenesis, a large body of evidence supports an important role for airway-derived nitric oxide (NO) in the mechanism underlying asthma. NO has effects as a bronchodialator via relaxation of airway smooth muscle [4] . NO binds to soluble Guanylate Cyclase (sGC); this leads to activation of the protein, followed by enhanced production of intracellular messenger cGMP, which is responsible for initiating downstream signaling for vasodilation [5] . Studies have established that sGC expression and activity are reduced in experimental asthma, and that this contributes to the observed airway hyperreactivity [6] . The sGC mRNA expression is transcrptionally regulated in culured cells by inflammatory stimuli, e.g. lipopolysaccharide, IL-1β or cytokines mixture. It may be that the high levels of inflammatory cytokines in asthmatic airways contribute to the lower level of sGC expression [6] [7] [8] . Furthermore, studies also identify an NO/cysteine interaction, in addition to the classical heme iron-NO activation, that is important in mediating activation of sGC; formation of a putative thiol-NO adduct apparently enables maximal sGC activation. However under oxidative stress, the thiol is oxidized, which prevents NO binding and retards sGC activation [9] . Thus, the oxidative stress in the asthmatic airway may contribute to deficient sGC-mediated bronchodilation through both the loss of sGC expression as well as cysteine oxidation that consequently abrogates maximal sGC activation via NO-cysteine interactions [9] . Considerable evidence supports detrimental effects of NO in airway inflammation through formation of reactive nitrogen species (RNS) that mediate inflammation and injury [1, 4] . Increased generation of RNS and reactive oxygen species (ROS) are well documented in asthma [10] [11] [12] . The asthmatic airways are infiltrated with eosinophils and neutrophils, which contain peroxidases, eg. eosinophilperoxidase (EPO) and myeloperoxidase (MPO) [13, 14] . The peroxidases use chloride and/ or bromide present in tissues to form hypohalous acids HOCl and HOBr [15] [16] [17] . Hypohalous acids are potent oxidants and chlorinate and/or brominate protein tyrosines to form 3-chlorotyrosine (Cl-Y) and 3-bromotyrosine [17] markers of MPO and EPO activity, respectively. MPO also uses the oxidation of nitrite (an oxidation product of NO) to generate the nitrogen dioxide radical [14, 15, 18 ] to nitrate protein tyrosine and form 3-nitrotyrosine [16, [18] [19] [20] . The detection of 3-nitrotyrosine in the lung of asthmatic patients provides definitive evidence for numerous biochemical targets of NO that are likely to have functional consequences in the asthmatic airway [13, 14, 18, 21] . This review will discuss the biochemical reactions of NO and its metabolic products in the pathophysiology of asthma.
Asthma and Oxidative Stress
Reactive oxygen species (ROS) are highly reactive molecules with unpaired electrons that can quickly react with other chemical compounds, potentially altering their structure and function [22] [23] [24] . Superoxide (O 2 •−) , hydrogen peroxide (H 2 O 2 ) and hydroxyl radicals ( • OH) are potent ROS in biological systems (Fig 1) . O 2 •− is unstable and reacts rapidly with proteins that contain transition-metal prosthetic groups, such as heme moieties or iron-sulfur clusters [25, 26] . Under normal condition, a very fine balance is maintained between ROS production and protection from oxidative injury by antioxidants, which include nonenzymatic (eg. vitamins and thiols) and enzymatic (eg. catalase, superoxide dismutases and glutathione peroxidase) mechanisms. During diseased conditions, an increased ROS production and/or reduced antioxidant defenses create an imbalance, resulting in oxidative stress, a final common pathway that generates and maintains inflammation and injury via proinflammatory cytokine release and altered enzymatic function [24] . Thus, oxidative stress, a condition representing an imbalance between oxidants and antioxidants in favor of the oxidants, is found to be involved in aging and various diseases, such as cancer, stroke, cardiovascular diseases and diabetes [27] . Measure of stable byproducts of oxidation has documented that oxidative stress is present in asthma. In a study by Ercan et al., children with asthma had higher plasma levels of malondialdehyde (MDA) and 8-isoprostanes (lipid peroxidation end product) compared with healthy controls and the MDA levels were higher in children with more severe asthma [28] . Acute asthma exacerbations worsen the degree of oxidative burden. Patients hospitalized for an acute asthma exacerbation, have higher levels of urinary oxidative metabolites and total plasma antioxidant capacity is also reduced during these episodes [29] [30] [31] . Furthermore, asthmatic subjects with more obstructed airways also have a higher degree of oxidative stress [32] .
Over the past two decades, a multitude of studies have revealed that in addition to oxidative stress in asthma, there is nitrative stress related to an increase of nitric oxide (NO) and its reaction products. NO, a relatively stable free radical, is increased in exhaled air of asthmatic individuals as compared to healthy individuals [33] . Individuals with asthma have 3-fold higher than normal NO concentrations in the lower airway and in the exhaled breath [14, [34] [35] [36] . Exhaled NO levels are inversely correlated with airflow parameters in asthmatic patients [37] [38] [39] [40] [41] . Exhaled NO in asthmatics increases during the late asthmatic response after experimental Ag challenge, a method used to mimic asthma attacks and study the mechanisms of episodic asthma in human subjects [34, 42] .
Nitric Oxide Synthases in Asthma
While antioxidants remove superoxide (O=O • ), there is no known nitric oxide (N=O • ) removal system. NO produced in the lungs is an important physiologic regulator of airway events, including airway tone, pulmonary vascular tone, mucin secretion, mucociliary clearance through effects on ciliary beat frequency and immune surveillance including tumoricidal and bactericidal effects [43] [44] [45] [46] .
Nitric oxide is formed when one of the chemically equivalent guanido groups of the essential amino acid L-arginine (L-arg) is oxidized by five electrons, forming NO • and Lcitrulline [47] . The reaction is catalyzed by enzymes nitric oxide synthases (NOS) with the help of several co-factors, including flavones (FAD, FMN), tetrahydrobiopterin (BH 4 ) and NADPH. The NOS exist in several isoforms (Table 1) ; all isoforms are stereospecific and active as homodimers [48] . NOS1 and NOS3, originally identified in neuronal and endothelial cells, respectively, depend on increases in calcium to bind calmodulin, leading to enzyme activation and picomolar levels of NO production [44] . NOS2 is inducible in diverse cell types by cytokines and contains calmodulin as a subunit, allowing the production of nanomolar levels of NO at resting levels of intracellular calcium [44] . All isoforms are present in the lung [49, 50] .
To investigate the role of NO in asthma, mice with targeted deletions of the three known isoforms of NOS (NOS1, 2, and 3) were studied using an established model of allergic asthma, the ovalbumin (OVA)-sensitized and challenged (OVA/OVA) mouse model. NOS2 isoform was significantly upregulated in the lungs of OVA/OVA wild-type (WT) mice and was undetectable in similarly treated NOS2-deficient mice. However airway hyperresponsiveness between these two groups were found to be similar, perhaps due to limitations of deletion models when there is genetic redundancy. Airway responsiveness in NOS1-deficient and NOS1/3-deficient mice was significantly less than that observed in WT mice. Overall, these studies support that NOS genotypes are associated with asthma [51] . In humans, the higher than normal NO concentrations in exhaled breath of is closely associated with increased transcriptional activation of the NOS2 gene [35, 52] .
Airway epithelium expresses NOS2 in the healthy lung [34, 53, 54] , where the high levels of NO are involved in innate host defense [46] . The NOS2 protein and activity are greatly increased in asthmatic airways [35, 55, 56] and inhibition of NOS2-derived NO attenuates antigen-induced airway constriction, inflammatory, and remodeling processes, reducing both collagen and elastic fiber deposition in a guinea pig model of allergic asthma [57, 58] . NOS2 gene expression is substantially regulated at the level of transcription [45, 46, [59] [60] [61] [62] . The expression of NOS2 is driven by a combination of the interferon-γ (IFN) activation of Janus kinase (JAK)/signal transducer and activator of transcription 1 (STAT-1) and activation of nuclear factor NF-κβ and AP-1 [44, [60] [61] [62] . IFNγ signal transduction is the primary molecular event required for the expression of NOS2 in airway human epithelia [54, 59, 63, 64] .
L-Arginine Metabolism By Arginase Regulates NO Synthesis
Model systems of allergic airway inflammation and studies in human asthma reveal that Larg metabolism is altered in asthma [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] . L-arg the substrate for NO synthases (NOS) is also the substrate for arginases [68, 76, 77] . The activity of NOS and arginases are coordinately regulated by L-arg availability (Fig. 2) [74] .
Asthmatic patients with acute asthma exacerbation have higher serum arginase activity and lower levels of L-arg as compared with healthy control subjects [71] . When L-arg is subsequently metabolized to NO via NOS, L-citrulline is produced. L-citrulline is converted via endogenous arginine synthetic pathways to L-arg; this may be an important source of Larg during prolonged NO synthesis by iNOS and enable the higher levels of exhaled NO found in asthmatic individuals [78] . In addition, increased levels of exhaled NO in asthma may also result from the nonenzymatic generation of NO from nitrite in the acid airway environment typical of asthma [79, 80] . Two isoforms of arginase enzymes may contribute to total arginase activity levels. Arginase I is highly expressed in the liver, where it serves a key role in the urea cycle, but is also present in cells that lack a complete urea cycle, which suggests other metabolic functions in nonhepatic tissues [81] . Arginase II is present in most tissues, including lung, and localized to the mitochondria within the cell [68, 71, 82, 83] .
Greater lung expression of both the Arginase I and II gene transcripts is present in the murine model of allergic asthma as compared with control mice [74] . The guinea pig model of allergic asthma also confirms higher arginase activity during the early response to allergen challenge [70] . In the murine model of asthma, greater L-arg metabolism through arginases linked to airway hyperreactivity [73] , suggesting that L-arg levels and its utilization by specific pathways may contribute to asthma pathophysiology. Kenyon et al have shown that treatment of mice with an arginase inhibitor increased the amount of NO produced in murine model of asthma [84] . Inhibition of arginase activity also increases protein S-nitrosylation and tyrosine nitration, and phenotypically enhances peribronchiolar and perivascular inflammation and mucus metaplasia in murine allergic asthma models [85] .
Sapienza et al showed that inhalation of L-arg amplifies the inflammatory response in the asthmatic airways [86] . Genetic studies in humans reveal that arginase I and II singlenucleotide polymorphisms are associated with an increased relative risk for asthma and atopy; the effect of polymorphisms on arginase expression or functional activity in humans is still unknown [87] . Nevertheless, it is clear that L-arg/NO metabolism is a determinant of asthmatic airway inflammation.
NO in Oxidation Chemistry: Nitrative Stress
The functional role of NO in biological systems depends on its concentration and association with other biomolecules and proteins [88, 89] . Furthermore it is clear that byproducts of NO reactions can also have biological roles. NO reacts with oxygen or superoxide to form nitrite (NO 2 − ), nitrate (NO 3 − ) and reactive nitrogen species (RNS), such as peroxynitrite (Fig 2) . In comparison to healthy controls, asthmatics have higher levels of NO, NO 3 − , and nitrotyrosine in the airways. Within minutes of an allergen-induced asthmatic response, NO 3 − increases markedly in asthmatics, while NO 2 − does not change, and NO decreases.
Kinetic modeling suggests that NO reacts rapidly with O 2 •− produced by oxidative burst of leucocytes to produce ONOO − , which may decay to NO 3 − or cause the nitration of phenolic compounds [14, 90] .
The half-life of peroxynitrite of 1 second at 37°C at pH 7.4 [57] . Peroxynitrite is in equilibrium with peroxynitrous acid (ONOOH), which can covalently modify protein tyrosyl residues through nitration, leading to structural change and potential alterations in biological function [91] [92] [93] [94] . In acid environments, ONOO − is protonated to yield peroxynitrous acid (ONOOH) can also react with thiol residues to form S-nitrosothiols (SNO), which function in unique signal transduction pathways in the cell [95] [96] [97] [98] . Consistent with the ability of ONOOH to participate in nitration and nitrosylation reactions, GSNO levels increase in parallel to nitrotyrosine in asthmatic airways after allergen challenge in direct proportion to formation of reactive nitrogen species [14] .
NO 2 − is a substrate for hemeperoxidases such as MPO and EPO. Peroxidase-catalyzed oxidation of NO 2 − results in the formation of nitrogen dioxide radical (NO 2 • ) or related molecules [3, 15, 21, [99] [100] [101] . Final products of hemeperoxidases include 3-nitrotyrosine and dityrosine (Fig 3) . In vitro studies have demonstrated that tyrosine nitration can cause either a gain or loss of protein function [102] [103] [104] [105] [106] . On average, proteins are composed of 4% tyrosine residues; but, chemical nitration of isolated proteins modifies only a subset of tyrosine residues, and the basis for this selectivity is not fully understood. This suggests that an innate property of the target protein or its location may predispose it toward nitration [107] . Nitration is likely not reversible and represents a pathophysiological modification, yet some reports have suggested that nitrated proteins can be repaired by a denitrase enzymic activity that is substrate dependent [108, 109] . However, denitrase enzyme needs to be purified and further characterized in relevance to its repair activity. Biological nitration of protein tyrosine is associated with over 50 diseases including transplant rejection, lung infection, central nervous system and ocular inflammation, shock, cancer, neurological disorders (e.g., amylotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and stroke), and asthma [35, 48, [110] [111] [112] [113] [114] .
Previous studies have shown that ONOO − induces airway hyper-responsiveness in guinea pigs in vitro and in vivo [115] . Immunohistochemical studies, using antibodies to nitrotyrosine, have been used to identify modified proteins and suggest a possible involvement of NO-derived oxidants in asthma [48, 114] . Enhanced nitrotyrosine staining is present in airways of asthmatic lung [18, 48, 114] . Subsequent immunolocalization studies revealed that both airway epithelium and eosinophils are major cellular sources for nitrotyrosine formation in asthmatic airways [14] . Protein modification through nitration in asthma has been conclusively shown by mass spectrometry-based quantification, which demonstrates 10-fold increases in nitrotyrosine content in proteins recovered from airways of subjects with asthma compared to non-asthmatic controls [18] . Using NOS2-deficient mice in a model of allergen-induced asthmatic response, nitrotyrosine was absent in airway epithelial cells, but eosinophil recruitment and hyper-responsiveness were still present, suggesting that asthmatic response can occur independent of reactive nitrogen species production [116] .
In vitro studies have shown that reactive oxygen and nitrogen species lead to oxidative and nitrative modification of tyrosine and inactivation of superoxide dismutases (SOD), MnSOD and ECSOD, while another major superoxide dismutase CuZnSOD can be inactivated by ROS and RNS through targeting of critical histidine residues and formation of histidinyl radicals [105, 117, 118] . As SOD scavenges superoxide, inactivation of this particular type of enzyme may contribute to cell injury through increased free radical damage [105] .
The ovalbumin sensitized and challenged mouse model of asthma has allowed for careful dissection of NO biochemical events [11] . In this model, mice were immunized with ovulbumin and two weeks later challenged with ovulbumin aerosol daily [11] . The extent and range of protein nitration was determined by two-dimensional gel electrophoresis followed by proteomic analysis. Nitrated proteins are detected within days of allergen challenge of sensitized mice (Fig. 4) . Nitrotyrosine containing proteins, identified by antibody recognition, were subjected to tryptic digestion and the resulting peptides used to identify the protein by database searching (Table 2 ). Similar to previous reports, many of the modified proteins are key enzymes for energy production, such as pyruvate kinase, lactate dehydrogenase, malate dehydrogenase, aldolase A and glyceraldehyde phosphate dehydrogenase. This indicates that cells divert from glycosis to other metabolic pathways for energy within cells during the inflammatory response. Dihydropyriminidase related protein, which is involved in axonal growth and has been identified as a target of protein nitration in Alzheimer's disease [119] , was also identified as a target for nitration during the asthmatic response. Annexin II and III, members of the annexin superfamily of calcium and phospholipid binding proteins [120] , and annexin I, an important mediator of glucocorticoid action [15] are all nitrated in the experimental model of asthma.
Notably, catalase, MnSOD, glutathione S-transferase, antioxidant protein 2 and carbonic anhydrase II are nitrated in the murine model of asthma, although these enzymes are present in different compartments of the cell. Studies identify loss of activity of catalase and SOD in asthma [121] . MnSOD is nitrated in the asthmatic airways, but the dominant oxidant modifications are related to hydroxyl radical like oxidants presumably via Fenton or HaberWeiss chemical events [122] Nitration of MnSOD at tyr (Tyr34), which is in the active site of the enzyme, leads to loss of enzyme function, and tissue injury [123, 124] .
Other studies have shown that catalase and glutathione-S-tranferase activity are lost by exposure to reactive nitrogen species in vitro [125, 126] . Catalase activity is 50% lower in bronchoalveolar lavage of asthmatic lungs, as compared to healthy controls [11] . Catalase isolated from asthmatic airway epithelial cells has increased protein oxidation markers, including nitrotyrosine and chlorination and oxidation of sulfhydryls, linking oxidative modification to the reduced activity in vivo. Tyrosine oxidant modifications of catalase occur in asthma: chlorination of tyrosine by peroxidase-catalyzed halogenation, and oxidative cross-linking of tyrosine as monitored by dityrosine, a product of tyrosyl radical [11] . Interestingly, catalase contains a putative chlorination site (KXHY) at Tyrosine 236, which may influence the susceptibility of the enzyme to peroxidase activity [127] . Tyrosine modification itself is not likely the complete cause of the loss of catalase activity. Other oxidative modifications, specifically oxidation of the cysteine 377 to cysteic acid, contribute to activity loss of the enzyme [11] . Altogether, the studies provide a picture of an abundance of reactive oxygen and nitrogen biochemical reactions in the asthmatic airway, and the potential downstream pathologic consequences.
NO in the S-Nitrosation Reaction in Asthma
The covalent addition of NO to certain protein moieties, such as thiol residues of cysteines, is termed nitrosation and can promote altered expression or function of enzymes, structural and signaling proteins [128, 129] . Not all cysteine residues are equally susceptible to Snitrosylation. In fact, the majority of proteins are modified at a single critical cysteine residue [130] . The sources of nitrosylating groups might include nitrogen oxide species that originate exogenously or endogenously. For example, NOS activity can lead to SNO formation; each NOS isoform is capable of producing SNOs in multiple tissues, cells and subcellular compartments. SNO formation appears to depend on the microenvironment of the protein itself [131] [132] [133] [134] [135] . On the other hand, NO also may be exchanged between transition metal ion and thiols in proteins [136, 137] . In addition, binding of NOS to adaptor proteins may localize nitrosylation reactions, but there are many more nitrosylated substrates than NOS binding partners. Recent work by Kornberg et al suggests that the S-nitrosylated GAPDH functions as a nuclear nitrosylase via a redox signal transduction cascade mechanism [138, 139] . Nitrosothiols (RSNO) are important reservoirs of bioactive NO, able to take up and store NO for later release as needed. There are several mechanisms for the decomposition of RSNO to produce NO, including nonenzymatic catalysis with copper or reaction with ascorbate [140] [141] [142] [143] , as well as through enzymatic pathways that act on R-SNO, such as thioredoxin reductase [144] , xanthine oxidase [145] , Cu/Zn superoxide dismutase [146] . GSNO reductase [GSNOR; alcohol dehydrogenase 5 (EC 1.1.1.1)] catalyses the denitrosylation of S-nitrosoglutathione (GSNO), but not other protein SNO [128, 147] . The decomposition of GSNO leads to formation of NH 3 and oxidized glutathione (GSSG).
RSNO are found in the human airway lining fluid, with the most common derivative GSNO at levels of 0.2 to 0.5 μM [148, 149] . GSNO has clearly defined physiologic roles in the airways, including regulation of ciliary beat frequency, immune response and bronchodilation. The bronchodilatory effects of GSNO are largely cGMP independent [148, 150] and result from S-nitrosylation of ion channels, receptor systems, and other myocyte proteins [150] [151] [152] [153] . SNOs also have pulmonary vascular smooth muscle relaxant effects [152, 154, 155] , and thus serve as a mechanism to couple perfusion via vasodilation to ventilation via bronchodilation [155, 156] . GSNO also contributes to airway homeostasis by antimicrobial and anti-inflammatory properties [157] .
Many studies now definitively link GSNO deficiency to asthma pathophysiology [149, 158, 159] . RSNO are present at lower than normal levels in the tracheal aspirates of children with acute asthma exacerbations [149, 160] as well as in the bronchoalveolar lavage fluid of wellcontrolled asthmatic individuals [14] . Accelerated catabolism of GSNO in asthma results in the overall lower levels of GSNO and contributes to the consequent higher release of free NO as measured in exhaled breath of asthmatics [149] . Most accumulating evidence points to greater enzymatic catabolism of GSNO via GSNOR in asthma [161] . GSNOR-deficient mice, which are unable to break down GSNO and thus have high airway levels, are protected from airway hyper-reactivity in the murine ovulbumin asthma model [158] . Recently, Que et al have also shown that the low level of GSNO in asthmatic bronchoalveolar lavage fluid is inversely correlated with GSNOR expression in lung lavage cell lysates [159] . Furthermore, the GSNOR activity in bronchoalveolar lavage samples was higher in asthma as compared to healthy control subjects and was inversely related to the degree of airway hyperresponsiveness [159, 161] . Altogether, studies suggest that GSNO/ NO metabolism is a determinant of airway reactivity in asthma.
In addition to effects on bronchial smooth muscle and airway reactivity, nitrosylation also impacts pro-inflammatory signal transduction in asthma. NO attenuates NF-κB p50-p65 heterodimer DNA binding and inhibits pro-inflammatory gene transcription through Snitrosylation of the p50 subunit [162] . The p65 binding partner of p50 is also found to be Snitrosylated in cytokine stimulated cells [163] . S-nitrosylation of p65 inhibits NF-κB-dependent gene transcription, and nuclear levels of S-nitrosylated p65 correlate with decreased DNA binding of the p50-p65 heterodimer [163] . Very recently Olson et al have tested the therapeutic benefit of S-nitrosothiols in the murine model of ovalbumin induced allergic inflammation [164] . They found that instillation of GSNO suppressed NF-B activation, but did not significantly affect overall markers of inflammation or mucus metaplasia, which may suggest its bronchodilatory effects outweigh its anti-inflammatory properties.
Summary
There is definitive evidence for alterations in NO synthetic and catabolic pathways in asthma. There are greater levels of toxic RNS, and equally important, lower levels of beneficial RSNO in asthmatic airways. In contrast to stable nitration products, the labile nature of RSNO has presented challenges to comprehensive identification of in vivo targets in asthma. However, mass spectrometry and derivatization techniques are providing exciting insight into the wide array of events controlled by nitrosylation chemistry in the cell. In parallel, physiologic studies have identified that Arginine/NO metabolic processes regulate airway hyper-reactivity and inflammation, key components that define asthma. Detailed understanding of the biochemical pathways that control NO metabolism and its physiologic functions will enable future rational design of strategies to optimize levels of beneficial NO products, while limiting the formation of more damaging species, in the treatment of asthma. 
Research Highlights
• Asthma is a disease characterized by unique alterations in nitric oxide (NO) metabolism.
• Greater overall synthesis by the NO-synthase type 2 enzyme is accompanied by a shift towards more nitration of proteins in the airway, and less nitrosylation of critical thiol residues in proteins.
• The greater nitration of specific proteins has been associated with adverse effects on protein functions, while loss of S-nitrosothiol (SNO) products leads to loss of bronchodilator effects.
• Thus, the abnormal NO metabolism contributes to the defining features of asthma, including chronic airway inflammation, injury and bronchoconstriction. system can also promote protein nitration and/or halogenation. In presence of thiols (RSH), nitrite is also involved in nitrosylation reaction to produce S-nitrosothiols (RSNO).
Fig. 3. Tyrosine containing amino acid oxidation and cross-linked products
Protein oxidative damage mediated by peroxidase mediated reactive brominating species (HOBr), MPO-generated reactive chlorinating species (HOCl), reactive nitrating species (RNS), tyrosyl radical (Tyr · ), may be identified by stable products formed by each pathway. Biochim Biophys Acta. Author manuscript; available in PMC 2012 November 1.
